Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
…, O Molinier, R Corre, I Monnet, V Gounant… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
[HTML][HTML] A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with …
…, D Carmier, J Madelaine, J Otto, V Gounant… - Journal of Thoracic …, 2019 - Elsevier
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
…, A Cazes, C Danel, B Abbar, J Pluvy, V Gounant… - Lung cancer, 2019 - Elsevier
Introduction Tumor mutational burden (TMB) correlates with response to immune checkpoint
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
inhibitors (ICI) in advanced non-small-cell lung cancer (aNSCLC). We hypothesized that …
[HTML][HTML] Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position article
…, D Re, Z Adjtoutah, B Seitz-Polski, V Gounant… - European Journal of …, 2022 - Elsevier
Taking into account higher risk of severe coronavirus disease 2019 or death among patients
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …
with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in …
[HTML][HTML] Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients …
V Gounant, VM Ferré, G Soussi, C Charpentier… - Journal of Thoracic …, 2022 - Elsevier
Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
[HTML][HTML] Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma
…, I Monnet, J Mazières, F Barlesi, V Gounant… - Journal of Thoracic …, 2020 - Elsevier
Introduction Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …
not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype …
Six-month prognosis of patients with lung cancer admitted to the intensive care unit
…, A Parrot, A Lavole, PY Ancel, V Gounant… - Intensive care …, 2009 - Springer
Background Intensive care unit (ICU) admission of patients with lung cancer remains
debated because of the poor short-term prognosis. However, ICU admission of such patients …
debated because of the poor short-term prognosis. However, ICU admission of such patients …
[HTML][HTML] Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: The eNRGy1 global multicenter registry
PURPOSE Although NRG1 fusions are oncogenic drivers across multiple tumor types
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …
including lung cancers, these are difficult to study because of their rarity. The global eNRGy1 …
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study
…, R Lacave, A Pujals, N Girard, C Callens, V Gounant… - Lung Cancer, 2019 - Elsevier
Objectives The understanding of histo-molecular mechanisms associated with resistance to
osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-…
osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-…